Patents by Inventor Arthur B. Pardee
Arthur B. Pardee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7153700Abstract: The present invention relates to methods for detecting the presence of SIX1 protein or nucleic acid in a biological sample in which a biological sample is contacted with an agent capable of detecting SIX1 protein or mRNA such that the presence of SIX1 is detected in the biological sample. Diagnostic and prognostic methods utilizing HSIX1 as an indicator of cancer and cancer progression are also provided. Compositions and kits for detecting the presence of SIX1 in a biological sample are also described.Type: GrantFiled: March 26, 1999Date of Patent: December 26, 2006Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Arthur B. Pardee, Heide L. Ford
-
Patent number: 7070797Abstract: Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably ?-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.Type: GrantFiled: July 31, 2002Date of Patent: July 4, 2006Assignee: Dana Farber Cancer Institute, Inc.Inventors: Arthur B. Pardee, Kenneth Anderson, Deepak Gupta, Chiang Li, Youzhi Li
-
Patent number: 6875745Abstract: We have discovered that the administration of a G1 and/or S phase drug such as ?-lapachone in combination with a G2/M drug such as a taxane derivative such as paclitaxel resulted in a greater than additive (i.e., synergistic) reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed. The present invention relates to a method for treating a mammalian tumor using combinations such as a taxane derivative, preferably paclitaxel, and a ?-lapachone, or a derivative or analog thereof.Type: GrantFiled: October 9, 2003Date of Patent: April 5, 2005Assignee: Dana Farber Cancer Institute, Inc.Inventors: Arthur B. Pardee, Chiang J. Li, Youzhi Li
-
Publication number: 20040126385Abstract: A method of screening, diagnosing, or treating an NF-&kgr;B induced pathology through the use of NF-&kgr;B modulating agents. These cells isolated from pathological regions of a subject can be cultured in the presence or absence of a modulating agent to detect a change in proliferation of the cells, wherein a change in proliferation in modulator treated cells compared to control cells shows that the cells are derived from an NF-&kgr;B induced pathology. A subject that contains cells derived from an NF-&kgr;B induced pathology can be diagnosed with this pathology. NF-&kgr;B modulators can then be used to treat the NF-&kgr;B induced pathology.Type: ApplicationFiled: August 27, 2002Publication date: July 1, 2004Inventors: Debajit K. Biswas, Arthur B. Pardee
-
Publication number: 20040087610Abstract: We have surprisingly discovered that the administration of a G1 and/or S phase drug such as &bgr;-lapachone in combination with a G2/M drug such as a taxane derivative such as paclitaxel resulted in an unexpected greater than additive (i.e., synergistic) reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed. The present invention relates to a method for treating a mammalian tumor using combinations such as a taxane derivative, preferably paclitaxel, and a &bgr;-lapachone, or a derivative or analog thereof.Type: ApplicationFiled: October 9, 2003Publication date: May 6, 2004Inventors: Arthur B. Pardee, Chiang J. Li, Youzhi Li
-
Patent number: 6664288Abstract: We have surprisingly discovered that the administration of a G1 and/or S phase drug such as &bgr;-lapachone in combination with a G2/M drug such as a taxame derivative such as paclitaxel resulted in an unexpected greater than additive (i.e., synergistic) reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed. The present invention relates to a method for treating a mammalian tumor using combinations such as a taxane derivative, preferably paclitaxel, and a &bgr;-lapachone, or a derivative or analog thereof.Type: GrantFiled: February 7, 2002Date of Patent: December 16, 2003Assignee: Dana Farber Cancer Institute, Inc.Inventors: Arthur B. Pardee, Chiang J. Li, Youzhi Li
-
Publication number: 20030036515Abstract: Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably &bgr;-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.Type: ApplicationFiled: July 31, 2002Publication date: February 20, 2003Inventors: Arthur B. Pardee, Kenneth Anderson, Deepak Gupta, Chiang Li, Youzhi Li
-
Publication number: 20020169135Abstract: Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably &bgr;-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.Type: ApplicationFiled: November 7, 2001Publication date: November 14, 2002Inventors: Arthur B. Pardee, Kenneth Anderson, Deepak Gupta, Chiang Li, Youzhi Li
-
Patent number: 5965409Abstract: A system for isolating mRNAs as cDNAs employs a polymerase amplification method using at least two oligodeoxynucleotide primers. In one approach, the first primer contains sequence capable of hybridizing to a site immediately upstream of the first A ribonucleotide of the mRNA's polyA tail and the second primer contains arbitrary sequence. In another approach, the first primer contains sequence capable of hybridizing to a site including the mRNA's polyA signal sequence and the second primer contains arbitrary sequence. In another approach, the first primer contains arbitrary sequence and the second primer contains sequence capable of hybridizing to a site including the Kozak sequence. In another approach, the first primer contains a sequence that is substantially complementary to the sequence of a mRNA having a known sequence and the second primer contains arbitrary sequence.Type: GrantFiled: July 19, 1996Date of Patent: October 12, 1999Assignee: Dana-Farber Cancer InstituteInventors: Arthur B. Pardee, Peng Liang
-
Patent number: 5665547Abstract: A method for comparing amounts or levels mRNAs employs a polymerase amplification method using at least two oligodeoxynucleotide primers. In one approach, the first primer contains sequence capable of hybridizing to a site immediately upstream of the first A ribonucleotide of the mRNA's polyA tail and the second primer contains arbitrary sequence. In another approach, the first primer contains sequence capable of hybridizing to a site including the mRNA's polyA signal sequence and the second primer contains arbitrary sequence. In another approach, the first primer contains arbitrary sequence and the second primer contains sequence capable of hybridizing to a site including the Kozak sequence. In another approach, the first primer contains a sequence that is substantially complementary to the sequence of a mRNA having a known sequence and the second primer contains arbitrary sequence.Type: GrantFiled: April 25, 1995Date of Patent: September 9, 1997Assignee: Dana Farber Cancer InstituteInventors: Arthur B. Pardee, Peng Liang
-
Patent number: 5599672Abstract: A method for isolating mRNAs as cDNAs employs a polymerase amplification method using at least two oligodeoxynucleotide primers. In one approach, the first primer contains sequence capable of hybridizing to a site immediately upstream of the first A ribonucleotide of the mRNA's polyA tail and the second primer contains arbitrary sequence. In another approach, the first primer contains sequence capable of hybridizing to a site including the mRNA's polyA signal sequence and the second primer contains arbitrary sequence. In another approach, the first primer contains arbitrary sequence and the second primer contains sequence capable of hybridizing to a site including the Kozak sequence. In another approach, the first primer contains a sequence that is substantially complementary to the sequence of a mRNA having a known sequence and the second primer contains arbitrary sequence.Type: GrantFiled: December 8, 1994Date of Patent: February 4, 1997Assignees: Dana-Farber Cancer Institute, Inc., The President and Fellows of Harvard CollegeInventors: Peng Liang, Arthur B. Pardee, Cesario F. Bianchi
-
Patent number: 5543291Abstract: A method of detecting carcinoma, particularly breast carcinoma, in a test sample of tissue, comprising assessing the expression cyclin E, or the amplification of cyclin genes, particularly the cyclin E gene, is disclosed. Altered expression of cyclins, such as overproduction of cyclins, particularly cyclin E, or production of alternative cyclin E proteins, as well as deranged appearance of mitotic cyclins during the cell cycle, are indicative of the presence of carcinoma. Amplification of cyclin genes, particularly the cyclin E gene, is also indicative of the presence of carcinoma.Type: GrantFiled: January 29, 1993Date of Patent: August 6, 1996Assignee: Dana Farber Cancer InstituteInventors: Khandan Keyomarsi, Arthur B. Pardee
-
Patent number: 5262311Abstract: A method for isolating mRNAs as cDNAs employs a polymerase amplification method using at least two oligodeoxynucleotide primers, one being short with arbitrary sequence and another being either short with arbitrary sequence or being capable of hybridizing to the region near the mRNA polyA tail. The oligodeoxynucleotide that is capable of hybridizing to the region near the polyA tail is used as a primer for reverse transcription of the mRNA and the resultant cDNA is amplified with a polymerase using both oligodeoxynucleotides as a primer set.Type: GrantFiled: March 11, 1992Date of Patent: November 16, 1993Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Arthur B. Pardee, Peng Liang